Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017)
Jazz Pharmaceuticals (JAZZ) posted quarterly Short-term Investments of $200.0 million for Q3 2017, up 236.6% year-over-year from $59.4 million in Q3 2016, and up 150.0% quarter-over-quarter from $80.0 million in Q2 2017.
Powered by 
Analysis
Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017) Analysis & Trends
Jazz Pharmaceuticals' Short-term Investments history runs 4 years deep, the most recent figure standing at $200.0 million for Q3 2017.
- In Q3 2017, Short-term Investments rose 236.6% year-over-year to $200.0 million; the TTM figure through Sep 2017 stood at $200.0 million (up 236.6% YoY), while the FY2016 annual figure was $60.0 million, changed N/A from the prior year.
- Short-term Investments for Q3 2017 stood at $200.0 million, up from $80.0 million in the prior quarter.
- The five-year high for Short-term Investments was $200.0 million in Q3 2017, with the low at $764000.0 in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.60 Bn | 13.98 Bn | 1.09 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 200.00 Mn |
| Jun 30, 2017 | 80.00 Mn |
| Mar 31, 2017 | 60.00 Mn |
| Dec 31, 2016 | 60.00 Mn |
| Sep 30, 2016 | 59.42 Mn |
| Jun 30, 2016 | 48.41 Mn |
| Mar 31, 2016 | 764,000.00 |
| Mar 31, 2012 | 73.56 Mn |
| Dec 31, 2011 | 75.82 Mn |
| Sep 30, 2011 | 12.13 Mn |